sprite-preloader
Anzeige
Mehr »
Dienstag, 21.11.2017 Börsentäglich über 12.000 News von 570 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A1XA8R ISIN: DK0060534915 Ticker-Symbol: NOVC 
Aktie:
Branche
Pharma
Aktienmarkt
OMX Copenhagen 20
STOXX Europe 50
1-Jahres-Chart
NOVO NORDISK A/S Chart 1 Jahr
1-Woche-Intraday-Chart
NOVO NORDISK A/S 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
43,817
44,257
22:26
43,925
44,054
22:01
09.02.2017 | 14:52
(32 Leser)
Schrift ändern:
(0 Bewertungen)

GlobeNewswire (Europe)·Mehr Nachrichten von GlobeNewswire (Europe)

Bagsværd, Denmark, 9 February 2017 - Novo Nordisk A/S has filed its Annual Report 2016 on Form 20-F for the financial year 2016 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2016. The reports are available at the SEC's website, www.sec.gov (http://www.sec.gov/index.htm), as well as on novonordisk.com (http://www.novonordisk.com/annualreport).

Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form on novonordisk.com (http://www.novonordisk.com/annualreport) or upon request to chqt@novonordisk.com (mailto:chqt@novonordisk.com) - please state the exact mailing address and the document(s) you wish to receive.

Further information

Media:    
Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com (mailto:amhg@novonordisk.com)
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com (mailto:kiau@novonordisk.com)
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com (mailto:phak@novonordisk.com)
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com (mailto:mrz@novonordisk.com)
Hanna Ögren +45 3079 8519 haoe@novonordisk.com (mailto:haoe@novonordisk.com)
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com (mailto:armk@novonordisk.com)
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com (mailto:kpvj@novonordisk.com)

 


Read the press release (http://hugin.info/2013/R/2077323/781453.pdf)


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire


© 2017 GlobeNewswire (Europe)